EMMAC to partner with Hyris Ltd to develop Unique Real-Time Phyto-Cannabinoid Rich technology for the specific identification of proprietary cultivars of Cannabis subsp

London, 24 June 2019: EMMAC, the European independent medical cannabis company, is pleased to announce an exclusive collaboration with Hyris Ltd, a UK-based biotechnology company, to develop a comprehensive library of genetic profiles of existing cannabis varieties, and to industrialise DNA-based methods for the identification of its unique branded cultivars.

The Hyris platform will enable EMMAC to gain an exact overview of available cannabis species as well as run specific DNA-based tests for the positive identification of EMMAC proprietary strains, ensuring industry-leading quality control, regulatory compliance and anti-counterfeiting assurance for customers and partners.

The portable, distributed testing platform ensures that all stakeholders (industrial, agronomy, Pharma, patients’ advocacy, regulators) from multiple geographies are able to participate in the creation and exchange of data through a proprietary cloud-based platform in real time, ensuring immediate access to the latest required information.

Barbara Pacchetti, Chief Scientific Officer of EMMAC, commented: “EMMAC is committed to investing in the latest innovations in cannabis cultivation, extraction, production and other value-adding associated technologies, to ensure the highest quality medical cannabis product for our customers. The Hyris platform enables us to provide industry-leading quality assurance for our products, across geographies in real-time to our multiple stakeholders.”

Stefano Lo Priore, CEO of Hyris, commented: “We are excited about this partnership and look forward to providing value to EMMAC, its partners, customers and regulators. As an emerging leader in the DNA-based analysis of plants, Hyris looks forward to the growing number of diverse stakeholders able to generate and process highly relevant genetic data to ensure quality, traceability and compliance.”


EMMAC Life Sciences Ltd is the European medical cannabis company, working to join together the latest science and research with cutting-edge cultivation, extraction and production. With supply and distribution partnerships throughout Europe, EMMAC is working to establish itself as both a thought leader in the industry, as well as the European leader in the production and supply of medical cannabis, hemp and other derivative products.


Hyris is a privately held, UK-based biotechnology company founded in 2014 by an entrepreneurial team with deep experience in biotechnology and electronics. The company offers its partners and clients disruptive technologies that enable genetic testing of biological samples in any setting, at any time, all available in real time on dedicated software platforms.

Further information on Hyris: www.hyris.net

Hyris Press Contacts:
Olga Tymoshenko office@hyris.net
Lorenzo Colombo lorenzo.colombo@hyris.net
Tel. +44.2039361227

For scientific enquiries please contact research@emmac.com
For general enquiries please contact info@emmac.com or visit www.emmac.com

Media enquiries:
Henry Harrison-Topham / Jamie Hooper / Ariadna Peretz Tel: +44 (0) 20 7466 5000
emmac@buchanan.uk.com www.buchanan.uk.com


All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of EMMAC Life Sciences Ltd. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.

Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. EMMAC Life Sciences Ltd assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.